Research News for 2011
-
Adding Avastin Slows Growth of Metastatic, HER2-Positive Disease
A study has found that adding Avastin (chemical name: bevacizumab) to a combination of Herceptin (chemical name: trastuzumab) and Taxotere (chemical name: docetaxel) increased the likelihood of respond...
-
Arimidex-Faslodex Combo Improves Survival in Metastatic Breast Cancer
A study has found that postmenopausal women diagnosed with hormone-receptor-positive metastatic breast cancer and treated with a combination of Arimidex and Faslodex as the first treatment for metastatic disease lived 6 months longer than women treated only with Arimidex.
-
Experimental Omnitarg May Help Treat Metastatic, HER2-Positive Disease
Research suggests that adding the experimental medicine Omnitarg to a combination of Herceptin and Taxotere slows the growth of metastatic HER2-positive breast cancer more than Herceptin and Taxotere alone.
-
Heart Problems Caused by Herceptin May Be More Common Than Thought
A small study has found that after 3 months of Herceptin treatment nearly 58% of women had some loss of heart function.
-
Experts Release Report Detailing Environmental Breast Cancer Risks
An expert report says that combination HRT, being overweight after menopause, and drinking alcohol are definitely linked to higher breast cancer risk.
-
Afinitor Helps Slow Growth of Certain Advanced-Stage Breast Cancers
New information from the BOLERO-2 study shows that women diagnosed with hormone-receptor-positive, HER2-negative advanced-stage or metastatic breast cancer who got Afinitor and Aromasin in combination lived more than twice as long without the cancer growing than women who got only Aromasin.
-
OncotypeDx Test Can Help Decide if Radiation Needed After DCIS Surgery
The OncotypeDx test can help doctors decide if women diagnosed with DCIS need radiation therapy.
-
Research Finds Links Between Obesity, Diabetes, and Breast Cancer
A very large study has found links between higher breast cancer risk and diabetes and obesity.
-
Brachytherapy May Not Be as Effective as Whole-Breast Radiation in Reducing Recurrence Risk
Results from a large study suggest that brachytherapy may not be as effective as whole-breast radiation therapy at preventing breast cancer recurrence.
-
Xgeva More Likely to Cause Osteonecrosis of the Jaw in Women Diagnosed with Advanced-Stage Breast Cancer
Research suggests that people diagnosed with advanced-stage breast or prostate cancer who get Xgeva are about twice as likely to develop osteonecrosis of the jaw compared to people with other advanced-stage cancers treated with Xgeva.
